

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Sep 2026

Evaluation of Terminalia chebula extract in preventing contrast media-induced nephrotoxicity

Protocol summary

Study aim

1. Determination of mean serum creatinine levels in the intervention and control groups on day zero (before treatment) and 72 hours after treatment
2. Determination of mean BUN levels in the intervention and control groups on day zero (before treatment) and 72 hours after treatment
3. Determination of mean urine output in the intervention and control groups on day zero (before treatment) and 72 hours after treatment

Design

Randomized controlled clinical trial

Settings and conduct

Hospitals affiliated to Isfahan University of Medical Sciences, Al-Zahra, Khurshid and Chamran hospitals

Participants/Inclusion and exclusion criteria

Inclusion criteria: 1. Age over 18 years 2. Receiving iodine-containing laxatives 3. eGFR over 60 (using the CKD-EPI formula) Exclusion criteria: 1. Age over 65 years 2. Concomitant intake of other nephrotoxic drugs (such as vancomycin, aminoglycosides, amphotericin-B, colistin, cisplatin, calcineurin inhibitors) 3. Failure to complete the study by the end of the third day 4. Pregnancy and lactation

Intervention groups

For the case group, 1000 mg of Helilah extract (two capsules) will be administered every 12 hours, starting 6 hours before the patient is injected with contrast material and continuing for 3 days until the patient has completely eliminated the contrast material. The control group will receive only the usual ward protocol, which includes hydration.

Main outcome variables

In this study, changes in Cr, BUN, eGFR, and urinary output are examined as primary outcomes and the incidence of acute renal failure as secondary outcomes

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20160713028901N8**
Registration date: **2026-06-22, 1405/04/01**
Registration timing: **prospective**

Last update: **2026-06-22, 1405/04/01**

Update count: **0**

Registration date

2026-06-22, 1405/04/01

Registrant information

Name

Shirinsadat Badri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3792 7068

Email address

badri@pharm.mui.ac.ir

Recruitment status

recruiting

Funding source

Expected recruitment start date

2026-07-23, 1405/05/01

Expected recruitment end date

2027-07-22, 1406/04/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of Terminalia chebula extract in preventing contrast media-induced nephrotoxicity

Public title
Terminalia chebula extract in preventing nephrotoxicity

Purpose
Prevention

Inclusion/Exclusion criteria
Inclusion criteria:
Age over 18 years Received iodinated contrast agent
eGFR over 60 (using CKD-EPI formula)
Exclusion criteria:
Age over 65 years Concomitant administration of other
nephrotoxic drugs (e.g. vancomycin, aminoglycosides,
amphotericin-B, colistin, cisplatin, calcineurin inhibitors)
Failure to complete the study by the end of the third day
Pregnancy and lactation

Age
From **18 years** old to **65 years** old

Gender
Both

Phase
3

Groups that have been masked
No information

Sample size
Target sample size: **86**

Randomization (investigator's opinion)
Randomized

Randomization description
Random sequence generation will be performed using
block randomization with variable block sizes. The
randomization sequence will be generated using the
Randomization.com software. Block sizes will vary
randomly between 6 and 9 to prevent predictability of
allocation. The sequences will be placed in sealed,
numbered envelopes, and treatment allocation will be
determined based on the order of patient enrollment.

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Research Ethics Committee of the Faculties of
Pharmacy and Nutrition -Isfahan University of Medical
Street address
Isfahan University of Medical Sciences and Health
Services, Hezar Jarib St.
City
Isfahan
Province

Isfahan
Postal code
8174673461
Approval date
2026-04-05, 1405/01/16
Ethics committee reference number
IR.MUI.PHANUT.REC.1405.006

Health conditions studied

1

Description of health condition studied
Nephrotoxicity
ICD-10 code
N17.9
ICD-10 code description
Acute kidney failure, unspecified

Primary outcomes

1

Description
eGFR changes
Timepoint
At baseline and at the end of treatment (after 72 hours)
Method of measurement
Calculation with the CKD-EPI formula

2

Description
changes in creatinine serum level
Timepoint
At baseline and at the end of treatment (after 72 hours)
Method of measurement
measuring creatinine level in serum sample

3

Description
changes in BUN level
Timepoint
At baseline and at the end of treatment (after 72 hours)
Method of measurement
measuring BUN level in blood sample

4

Description
changes in urine output
Timepoint
At baseline and at the end of treatment (after 72 hours)
Method of measurement
measuring urine volume

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: All patients will be hydrated before receiving the contrast agent according to the center's guidelines and protocol, as 1 mL/kg/hour of normal saline for 6 to 12 hours before receiving the contrast agent and 1 mL/kg/hour of normal saline for 6 to 12 hours during and after receiving the contrast agent. For the intervention group, 1000 mg of Helilah extract (two capsules) every 12 hours, starting 6 hours before the contrast agent injection for the patient and continuing for 3 days until the contrast agent is completely excreted from the patient.

Category

Prevention

2

Description

Control group: All patients will be hydrated before receiving the contrast agent according to the center's guidelines and protocol, as 1 mL/kg/hour of normal saline for 6 to 12 hours before receiving the contrast agent and 1 mL/kg/hour of normal saline for 6 to 12 hours during and after receiving the contrast agent. The control group will not receive any medication other than the center's standard protocol.

Category

Prevention

Recruitment centers

1

Recruitment center

Name of recruitment center

Al-Zahra hospital

Full name of responsible person

Shirin Sadat Badri

Street address

Al-Zahra hospital , Sofeh Boulevard, Shahid Keshvari Highway

City

Isfahan

Province

Isfahan

Postal code

8174675731

Phone

+98 31 3822 0000

Email

badri@pharm.mui.ac.ir

2

Recruitment center

Name of recruitment center

Khorshid Hospital

Full name of responsible person

Shirin Sadat Badri

Street address

Khorshid Hospital, Ostandari Street

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3668 0048

Email

badri@pharm.mui.ac.ir

3

Recruitment center

Name of recruitment center

Chamran Hospital

Full name of responsible person

Shirin Sadat Badri

Street address

Chamran Hospital, Salman Farsi street

City

Isfahan

Province

Isfahan

Postal code

8158388997

Phone

+98 31 3260 0961

Email

badri@pharm.mui.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Mehdi Asgari

Street address

Hezar jerib

City

Isfahan

Province

Isfahan

Postal code

8174673461

Phone

+98 31 3668 8064

Fax

Email

res@mui.ac.ir

Web page address

<https://research.mui.ac.ir/fa>

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes
Title of funding source
Esfahan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shirinsadat Badri
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Hezar jarib street, Isfahan, iran.
City
Isfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3792 7068
Email
badri@pharm.mui.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shirinsadat Badri
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Hezar jarib street, Isfahan, iran.
City
Isfahan
Province
Isfahan
Postal code

8174673461
Phone
+98 31 3792 7068
Email
badri@pharm.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Shirinsadat Badri
Position
Associate Professor
Latest degree
Specialist
Other areas of specialty/work
Medical Pharmacy
Street address
Hezar jarib street, Isfahan, iran.
City
Isfahan
Province
Isfahan
Postal code
8174673461
Phone
+98 31 3792 7068
Email
badri@pharm.mui.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Initially, both inpatients and outpatients will be included in the study; medication will be administered in the hospital for inpatients and at home for outpatients. In both groups of patients, if testing and follow-up are not possible by the third day, the patient will be excluded from the study. As mentioned in the objectives, urine output will be measured only in inpatients.

When the data will become available and for how long

The start of the data access period will be in October 2027, after the defense of the thesis and the publication of the article resulting from the project.

To whom data/document is available

Researchers, students and teachers working in academic and medical institutions

Under which criteria data/document could be used

In order to design similar studies or use the results of this study for systematic review and meta-analysis of data

From where data/document is obtainable

Online scientific databases, including PubMed, Web of Science, Scopus, and... Website of Central Library of Isfahan University of Medical Sciences, address:

<https://diglib.mui.ac.ir/> or by sending an email to the corresponding author: badri@pharm.mui.ac.ir

What processes are involved for a request to access data/document

Searching with keywords in scientific internet databases, Search through the title of the project on the website of the digital library of Isfahan University of Medical Sciences. Internet search on the website of the magazine where the article from the project is published

Comments